1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Aimovig |
| structure | File | |
| classes | List of String, delimiter: , | Anti-CGRP receptor monoclonal antibody |
| mechanism | String | Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling |
| uses | String | Preventive treatment of migraine in adults (episodic and chronic) |
| starting_dose | String | 70 mg SC monthly; may increase to 140 mg monthly |
| preparations | String | 70 mg/mL or 140 mg/mL prefilled autoinjector |
| fda_max | String | 140 mg/month |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous |
| onset | String | Onset of preventive effect over weeks; some patients respond after first dose |
| duration | String | Monthly dosing |
| halflife | String | ~28 days |
| bioavailability | String | ~82% SC |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx |
